ASCO: Pembrolizumab Ups DFS in High - Risk Resected Clear - Cell RCC

Estimated DFS rate 77.3 and 68.1 percent at 24 months with pembrolizumab versus placebo; benefit consistent across subgroups
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Nephrology, Oncology, Pharmacy, Conference News, Source Type: news